Baird Financial Group
ORIC icon

Baird Financial Group’s Oric Pharmaceuticals ORIC Stock Holding History

Baird Financial Group’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,691
Closed -$87.6K – 1831
2025
Q1 		$87.6K Hold
15,691
– – ﹤0.01% 1725
2024
Q4 		$127K Hold
15,691
– – ﹤0.01% 1707
2024
Q3 		$161K Buy
15,691
+2,700
+21% +$26.7K ﹤0.01% 1673
2024
Q2 		$91.8K Buy
12,991
+650
+5% +$5.82K ﹤0.01% 1724
2024
Q1 		$170K Hold
12,341
– – ﹤0.01% 1690
2023
Q4 		$114K Buy
+12,341
New +$89.2K ﹤0.01% 1674

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Baird Financial Group's ORIC Position: Q2 2025 in Review

Baird Financial Group sold out of Oric Pharmaceuticals (ORIC) in Q2 2025, closing a stake of 15,691 shares — an estimated $87.6K sold.

Baird Financial Group first reported a position in ORIC in Q4 2023 and held it in 6 quarters. The position peaked at $170K in Q1 2024. 142 funds tracked by Wall St. Rank hold ORIC as of Q2 2025.

  • Baird Financial Group reported no remaining Oric Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Baird Financial Group sold 15,691 Oric Pharmaceuticals shares in Q2 2025, an estimated $87.6K.
  • Baird Financial Group first reported a position in Oric Pharmaceuticals in Q4 2023 and held it in 6 quarters.
  • Baird Financial Group's Oric Pharmaceuticals position peaked at $170K in Q1 2024.
  • 142 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2025.

Based on Baird Financial Group's 13F filing for Q2 2025, filed 13 Aug 2025.